Keywords: Boehringer Ingelhiem, Pradaxa, Bleeding risks, Current warnings, EMA

EMA says bleeding risks associated with Boehringer Ingelheim’s Pradaxa can be managed

Article | 20 November 2011

Print This

The European Medicines Agency on Friday providing an update on the safety of independent German drug major Boehringer Ingelheim’ ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in